|

RC48-ADC Clinical Trials

2 actively recruiting trials

Also known as: Disitamab Vedotin

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Shanxi Province Cancer Hospital1
  • RemeGen Co., Ltd.1

Indications

  • Urothelial Carcinoma2
  • Cancer2
  • HER2-expressing1

Other2 trials

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.